Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2067)	1/22/2008 3:49:36 PM
From: Jibacoa	Respond to of 3722

JNJ's volume is close to 2x its ADV for 2nd trading day on a roll, but the stock is still holding above its support at the $64 level.<g> stockcharts.com JNJ announced record sales of $16B for the 4thQ, an increase of 16.6% vs. 2006. US sales were up 9.1%,& international sales 25.8%. Earnings for the Q were $2.4B ($.82/shr.) Sales benefit from strong performance of RISPERDAL CONSTA, INVEGA, TOPAMAX, REMICADE, VELCADE, CONCERTA, & LEVAQUIN., Sales of PROCRIT were lower. JNJ said that its pipeline has several new drug applications submitted for approval, includeding: Paliperidone palmitate in the U.S. for the treatment of schizophrenia; Ustekinumab (CNTO 1275) in the U.S. & Europe, a new, human monoclonal antibody for the treatment of adult patients with chronic to moderate to severe plaque psoriasis; Dapoxetine in Europe for the treatment of premature ejaculation in men 18-64 years of age; VELCADE in Europe for the treatment of patients with previously untreated MM; & PREZISTA in the U.S. for the treatment of HIV in adult patients with no previous antiretroviral treatment. In Jan 2008, it received accelerated approval from the FDA for INTELENCE tablets, an anti-HIV medication. The stock is trading around 4.8xBV with a +CF around $4.60 The short ratio came up almost 10% & is close to 2x its ADV. The stock needs to close above the resistance at $67.50 & above $70 to make a 3Yrs. H <g> bigcharts.marketwatch.com Bernard